Hawaii Med-QUEST GLP-1 Coverage 2026: Pattern #50 CAPSTONE — Categorical AOM Exclusion With Active Bipartisan Reversal Legislation (SB 3195), 32-Year 1115 Demonstration Architecture, Six-Island Cold-Chain Logistics, and NHPI Prescribing Disparity (PMID 39574878)

1. Current coverage status (May 15, 2026)

2. The 1115 demonstration architecture (since August 1, 1994)

Hawaii is one of the original Section 1115(a) Medicaid demonstration waiver states. The current demonstration, formally titled "Hawaii QUEST Integration," bears CMS demonstration number 11-W-00001/9. Original implementation: August 1, 1994. CMS extension history:

The demonstration governs essentially all Hawaii Medicaid enrollees - in contrast to states (like Vermont Pattern #41 or North Dakota Pattern #44) where 1115 waivers cover narrow demonstration populations. Verbatim from the Med-QUEST 1115 page: "All eligible beneficiaries will continue to be enrolled under QUEST Integration, and access to services will be determined by clinical criteria and medical necessity." Three sub-programs operate within QUEST Integration:

• Standard QUEST Integration - the default population (low-income families, ACA expansion adults at 138% FPL, pregnant women, children, seniors, individuals with disabilities)
• Community Care Services (CCS) - individuals with serious mental illness
• Going Home Plus - institutional-to-community transitions

The 32-year continuous-demonstration record is a defining feature of Pattern #50. Most state Medicaid programs in the 50-state series operate primarily under the state-plan authority (Title XIX section 1902) with narrower 1115 waivers governing specific demonstration populations or services. Hawaii’s all-population 1115 demonstration architecture means that essentially every coverage policy decision - including the AOM exclusion - operates within the demonstration’s terms-and-conditions framework rather than under state-plan authority alone.

3. The five Med-QUEST MCOs

Med-QUEST operates through five managed care organizations. Verbatim from Med-QUEST: "There are five (5) MCO health plans: AlohaCare, HMSA, Kaiser Permanente, ’Ohana Health Plan, and UnitedHealthcare Community Plan that provides medical and Long Term Services and Support (LTSS) benefits."

The five-MCO architecture is dense by national standards - many states in the WLR 50-state series operate with two to four MCOs (e.g., RI Pattern #40 with NHPRI + UHC; DE Pattern #42 with Highmark + AmeriHealth Caritas + Delaware First Health; KS Pattern #43 with three KanCare MCOs). Hawaii’s five-MCO concentration reflects both the small population base (~1.4 million) and the historic 1115 architecture that brought multiple plans into the state pharmacy benefit administration framework. The five MCOs cover essentially the entire ~396,000-enrollee population, with FFS playing a residual role only.

4. The AlohaCare categorical exclusion verbatim

AlohaCare QUEST Formulary is the only Hawaii Med-QUEST MCO formulary with HTML-extractable content. The relevant exclusion language verbatim:

"Drugs for weight loss, erectile dysfunction, infertility, and cosmetic purposes are not covered."

This is a categorical bundled exclusion - the same architectural pattern observed in Vermont Pattern #41 (PDL effective April 17, 2026 verbatim: "Drugs used for weight loss, drugs used to promote fertility, and drugs used for cosmetic purposes or hair growth are excluded from coverage under the Vermont Medicaid Pharmacy program.") and Maine Pattern #39. The bundled-exclusion structure descends from federal Medicaid statute Section 1927(d)(2)(A) (42 U.S.C. section 1396r-8(d)(2)(A)), which gives state Medicaid programs the option to exclude six categories of drugs from coverage: (i) agents when used for anorexia, weight loss, or weight gain; (ii) agents when used to promote fertility; (iii) agents when used for cosmetic purposes or hair growth; (iv) agents when used for the symptomatic relief of cough and colds; (v) agents when used for the symptomatic relief of cough and colds; (vi) prescription vitamins and mineral products, except prenatal vitamins and fluoride preparations.

Hawaii’s AlohaCare exclusion bundles three of the six federal-statute optional-exclusion categories (weight loss, fertility, cosmetic purposes) plus erectile dysfunction (a state-level addition not enumerated in the federal statute). The exclusion is operational at the MCO formulary level rather than codified in a state administrative rule - one reason SB 3195 directs DHS to "orders both immediate and permanent rulemaking" in the bill’s reversal mechanism.

Hoodline / KITV verbatim reporting on SB 3195 (February 11, 2026) confirms the existence of the exclusion in current rule: "Under SB 3195, DHS would scrap Hawaii’s current exclusion on GLP-1 drugs used to treat obesity." The press coverage itself is one of the verbatim primary-source confirmations that an exclusion exists. The Rx Index 50-state tracker independently classifies Hawaii: "Not covered. Diabetes GLP-1s covered." KFF January 2026 GLP-1 tracker excludes Hawaii from the 13-state active-coverage cohort.

5. SB 3195 - the headline bipartisan reversal bill (2026 Regular Session)

SB 3195 is the active 2026 Hawaii Senate bill that would scrap the Med-QUEST AOM exclusion and is the single most consequential policy lever for Pattern #50. The bill’s distinguishing features are summarized below.

SB 3195’s distinctive features relative to the WLR 50-state series:

• Bipartisan sponsorship - distinguishes Hawaii from states where AOM reform attempts have been single-party (e.g., Maine LD 480, Vermont H.765 / S.164, Montana SB 417). Hawaii’s politically diverse co-sponsorship base is a structural advantage for the bill’s 2027 prospects if it died at 2026 sine die.
• PA-prohibition language - the bill explicitly states "prior authorization should not be required for eligible patients." This is more aggressive than the typical coverage-mandate-with-standard-PA structure seen in other state bills.
• Dual Medicaid + Medicare Part D scope - the bill extends to dually-eligible Medicare Part D beneficiaries, an unusual scope feature given that state legislatures typically cannot directly mandate Medicare Part D coverage (CMS administers Part D federally). The practical implementation mechanism is UNVERIFIED.
• Sponsor lived-experience framing - Sen. Fevella’s personal Mounjaro use for T2D and 80-pound weight loss creates an unusually direct sponsor-clinical-experience link absent in other series-tracked bills.

The bill remains in play for 2027 session action regardless of 2026 sine die status because Hawaii operates a two-year biennial legislative calendar. Patients and advocates should track capitol.hawaii.gov SB 3195 disposition and engage with Senate Health Committee members for the 2027 cycle.

6. PA pathway - the operational details

PA mechanics vary by MCO. UHC QUEST publishes the most operational detail and is summarized below; AlohaCare PA details follow.

6.1 UHC Community Plan QUEST

• Pharmacy PA fax: 866-940-7328
• Pharmacy PA phone: 1-800-310-6826
• Electronic PA: CoverMyMeds accepted
• Adjudication timeline: "Allow at least 24 hours for review" (UHC verbatim)
• Clinical documentation standard: "UnitedHealthcare Community Plan requires that the diagnosis for prescriptions in certain classes match the FDA-approved use or a use supported by current published evidence." (UHC verbatim)

6.2 AlohaCare

• Pharmacy PA phone: 808-973-7418 or 866-973-7418
• Pharmacy PA fax: 1-866-728-0233 or 1-877-252-5224
• Hours: 8 AM-5 PM Monday-Friday HST (Hawaii Standard Time = UTC-10; note that Hawaii does not observe Daylight Saving Time, so HST is 2-3 hours behind Pacific time depending on the time of year)

6.3 HMSA, Kaiser, ’Ohana

HMSA, Kaiser Permanente, and ’Ohana Health Plan publish their own PA submission portals and member-services lines accessible from the Med-QUEST MCO Formulary Search hub (medquest.hawaii.gov/en/plans-providers/pharmacy/drug-coverage/mco-formulary-search.html). Specific PA fax / phone / electronic submission detail is UNVERIFIED at the operational level for May 15, 2026 - the MCO PDLs render as binary PDFs blocking automated extraction.

6.4 What a PA submission looks like for a T2D-indicated GLP-1 in Hawaii

For a T2D-indicated GLP-1 (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus, Bydureon BCise), a PA submission typically requires:

• ICD-10 diabetes diagnosis (E11.9 for T2D without complications, or E11.x with specific complications)
• Recent hemoglobin A1C value (specific threshold UNVERIFIED per MCO)
• Prior trial of metformin and/or another oral antihyperglycemic agent (specific step-therapy duration UNVERIFIED per MCO)
• Quantity-limit attestation (most MCOs apply 28-30 day quantity limits)
• Prescribing clinician contact information and supervision attestation

For a weight-loss-indicated GLP-1 (Wegovy, Zepbound, Saxenda, Contrave): PA submissions will be denied under the current Med-QUEST categorical exclusion - no PA pathway exists at present. If SB 3195 is enacted and DHS completes rulemaking, the bill text explicitly removes the PA requirement: "prior authorization should not be required for eligible patients." The federal PA adjudication floor under 42 CFR section 438.210 applies across all MCOs: 14 calendar days standard, 72 hours expedited, with a 14-day expedited extension permitted in defined circumstances.

7. Appeals - the two-step architecture

Hawaii Med-QUEST appeals follow a two-step architecture: MCO-level appeal first, state fair hearing post-MCO-exhaustion.

7.1 Step 1 - MCO appeal

HMSA QUEST Integration publishes the most accessible verbatim appeal language and is summarized here. The same general framework applies across all five Med-QUEST MCOs by federal managed-care regulation (42 CFR Part 438 Subpart F).

• Filing deadline: "You have 60 days after an action occurs to file an appeal." (HMSA QUEST verbatim)
• Standard decision timeline: "We have 30 calendar days from the date we receive your appeal to give you our decision." (HMSA QUEST verbatim)
• Expedited review trigger: "You may file an expedited appeal if the standard appeal timeline could seriously jeopardize your life or health." (HMSA QUEST verbatim)
• Expedited decision timeline: "no more than three business days from the date we receive your expedited appeal request." (HMSA QUEST verbatim)

7.2 Step 2 - State fair hearing (post-MCO exhaustion)

• Filing deadline: "You must submit the appeal to the DHS Administrative Appeals Office within 120 days from the time you received our appeal decision." (Med-QUEST verbatim)
• Decision timeline: "DHS will make its decision within 90 days from the date the request was filed." (Med-QUEST verbatim)
• Mailing address: State of Hawaii Department of Human Services, Administrative Appeals Office, P.O. Box 339, Honolulu, HI 96809-0339

7.3 Eligibility appeals (separate from PA-denial appeals)

Eligibility appeals (challenges to whether you are eligible for Med-QUEST coverage at all - not the same as PA-denial coverage disputes) operate under a different 90-day window. Contacts:

• Phone: 800-316-8005
• Fax: 800-576-5504
• Mailing address: Med-QUEST Eligibility, P.O. Box 700190, Kapolei, HI 96709-0190
• Free legal representation: Available on request via Legal Aid Society of Hawaii

7.4 Practical denial-recovery for GLP-1 weight-loss PAs

Because the categorical Med-QUEST AOM exclusion is currently operational, an MCO appeal of a weight-loss-indicated GLP-1 denial will be sustained at the MCO level. The state fair hearing at the DHS Administrative Appeals Office is the medical-necessity-exception venue. Patients should consider: (1) framing the PA around a documented FDA-label-restricted indication (CV risk under Wegovy SELECT, OSA under Zepbound, MASH under Wegovy, pediatric chronic weight management under Wegovy >= 12) where applicable; (2) requesting expedited review on the basis that delaying GLP-1 therapy poses a life-or-health jeopardy; (3) engaging Legal Aid Society of Hawaii for representation in fair-hearing proceedings. Federal EPSDT (Early and Periodic Screening, Diagnostic, and Treatment) regulations at 42 U.S.C. section 1396d(r) provide an additional regulatory anchor for medical-necessity exceptions for beneficiaries under age 21.

8. Island geography and cold-chain logistics - Pattern #50 distinctive

Hawaii is the only US state composed entirely of islands. The practical implications for Med-QUEST pharmacy benefit delivery are operationally distinctive in the WLR 50-state series.

8.1 The six major inhabited islands

8.2 Cold-chain pen logistics

All injectable GLP-1 receptor agonists prescribed under Hawaii Med-QUEST require 2-8 C refrigerated storage per the FDA-approved prescribing information. Specifically:

• Ozempic (semaglutide injection) - 2-8 C until first use; up to 56 days at room temperature post-first-use
• Mounjaro (tirzepatide injection) - 2-8 C until first use
• Wegovy (semaglutide injection) - 2-8 C until first use
• Zepbound (tirzepatide injection) - 2-8 C until first use
• Victoza (liraglutide injection) - 2-8 C until first use
• Saxenda (liraglutide injection) - 2-8 C until first use
• Bydureon BCise (exenatide ER injection) - 2-8 C until first use
• Trulicity (dulaglutide injection) - 2-8 C until first use

Inter-island mail-order pharmacy fulfillment for these drugs requires temperature-monitored cargo. The two primary inter-island shipping channels are commercial air freight (Hawaiian Airlines cargo, Aloha Air Cargo, Mokulele Airlines) and US Coast Guard-overseen marine cargo. Both have cold-chain documentation protocols, but the operational cost and lead-time add friction that is invisible in the formulary-coverage discussion and very material for rural-island patients.

8.3 The rural-island access stratification

Patients on Moloka’i (population ~7,000, served primarily by Moloka’i General Hospital pharmacy) and Lana’i (population ~3,000) face the highest rural-island access friction. Even if SB 3195 is enacted and the categorical Med-QUEST AOM exclusion is scrapped, rural-island GLP-1 access will remain meaningfully constrained by dispensing-location density rather than by formulary coverage alone. Practical implication for Moloka’i and Lana’i patients: engage with the MCO member-services line about mail-order cold-chain fulfillment options well in advance of any planned dose escalation that requires an un-interrupted cold-chain supply. The interaction between geographic isolation, cold-chain temperature requirements, and dispensing-location density is one of the most operationally distinctive features of Hawaii Pattern #50 relative to any other state in the WLR 50-state series.

9. Cost of living and self-pay alternatives

Hawaii has the highest cost of living of any US state. The 2026 cost-of-living index is 193.3 per livinginhawaii.com - nearly double the national average of 100.0. This is the highest cost-of-living index in the WLR 50-state series. The Bureau of Labor Statistics Honolulu CPI separately confirms Honolulu inflation patterns exceeding mainland averages.

The practical implication for Hawaii Med-QUEST beneficiaries who do not qualify for the T2D coverage pathway and want GLP-1 access for chronic weight management: self-pay manufacturer cash-pay channels are the primary alternative. Per Ka Wai Ola (OHA publication) coverage of NHPI patients seeking access, Wegovy and Zepbound cash price "exceeding $1,000 a month without insurance" is consistent with the May 15, 2026 NovoCare Wegovy verification.

9.1 Manufacturer self-pay channels (May 15, 2026 verification)

The previous $499 baseline NovoCare Wegovy pricing tier was retired in May 2026. Current tiers verified via direct NovoCare retrieval on May 15, 2026.

9.2 Patient assistance programs

• Novo Nordisk PAP (Patient Assistance Program) - for Wegovy and other Novo Nordisk products. Income-tested. Application by mail. Processing time typically 4-8 weeks.
• Lilly Cares - for Zepbound and other Lilly products. Income-tested. Application by mail. Processing time typically 4-8 weeks.

9.3 Compounded telehealth options

LegitScript-approved compounded telehealth platforms offered compounded semaglutide at $99-$199/month and compounded tirzepatide at $149-$249/month as of May 2026. The FDA tirzepatide compounding-resolved declaration (October 2024) and semaglutide compounding-resolved declaration (February 2025) mean new compounded prescriptions for these molecules require documented patient-specific clinical need beyond the previous shortage justification. Hawaii cold-chain shipping adds the further operational consideration noted in section 8.2. Compounded GLP-1s are not covered by Med-QUEST under any pathway, consistent with all 49 prior states in the series.

10. Native Hawaiian / Pacific Islander obesity context

Native Hawaiian and Pacific Islander (NHPI) obesity epidemiology in Hawaii is one of the most distinctive demographic features of Pattern #50.

10.1 NHPI obesity prevalence

• HHS Office of Minority Health 2024 verbatim: "Native Hawaiian/Pacific Islander (NHPI) adults were 27% more likely than U.S. adults overall to have obesity."
• Hawaii state BRFSS 2009: 49.3% of Native Hawaiians are obese (UNVERIFIED for current NHPI-specific Hawaii BRFSS reporting)
• NHPI youth: NHPI high school boys "more than three times as likely as their peers to have obesity"
• Hawaii state average: 27.0% adult obesity rate (America’s Health Rankings 2026) - second-lowest in the US, but state average masks severe NHPI-specific disparity

10.2 PMID 39574878 - NHPI vs White GLP-1 prescribing disparity

The most clinically consequential finding for Pattern #50 is from PubMed PMID 39574878, a retrospective cohort study. The headline result: the adjusted odds ratio for tirzepatide receipt among NHPI patients vs. White patients was 0.4 (95% confidence interval 0.3-0.6) - NHPI patients receive GLP-1s at substantially lower rates than White patients with comparable clinical indications.

This prescribing disparity sits on top of (not in addition to) the higher NHPI obesity prevalence, compounding the equity gap. The convergence of three signals - high NHPI obesity prevalence, low NHPI GLP-1 prescription rate, and cultural framing in OHA-published materials - is the distinctive equity stack for Pattern #50 that no other state in the WLR 50-state series presents in the same combination.

10.3 Cultural framing in Ka Wai Ola (Office of Hawaiian Affairs publication)

Dr. Jodi Leslie Matsuo (Native Hawaiian registered dietitian) published a column titled "Is Semaglutide the Right Solution for Native Hawaiians?" in Ka Wai Ola - the publication of the Office of Hawaiian Affairs (OHA). Matsuo verbatim:

"Semaglutide offers significant benefits, but it is not a universal solution, especially for Native Hawaiians who face unique health challenges influenced by social determinants of health."

Matsuo recommends pairing pharmacotherapy with "traditional Hawaiian and other cultural foods... hula, surfing, walking... prayer, ho’oponopono." Ho’oponopono is a traditional Hawaiian practice of reconciliation and forgiveness, central to many traditional Hawaiian health frameworks.

The Ka Wai Ola column is a tribal-equivalent-publication framing that elevates social determinants of health and cultural practice alongside pharmacotherapy. Hawaii is the only state in the WLR 50-state series where a tribal-equivalent publication has authored a specific framing column on GLP-1 receipt for indigenous populations. This cultural-clinical-framing signal is one of the most distinctive features of Pattern #50 and is reinforced by the Med-QUEST coverage gap that constrains NHPI access to pharmacotherapy alongside cultural practice.

11. Pattern #50 in the 50-state taxonomy

With Hawaii Pattern #50 shipped, the full taxonomy of state Medicaid GLP-1 coverage patterns is now documented. The comparative position of Pattern #50 relative to the other 49 patterns is summarized below.

11.1 HI vs. Vermont Pattern #41 - closest formulary-language peer

Vermont Pattern #41 has the closest formulary-language match to Hawaii Pattern #50. The verbatim exclusion bundling is structurally identical:

• VT PDL effective April 17, 2026 verbatim: "Drugs used for weight loss, drugs used to promote fertility, and drugs used for cosmetic purposes or hair growth are excluded from coverage under the Vermont Medicaid Pharmacy program."
• HI AlohaCare QUEST Formulary verbatim: "Drugs for weight loss, erectile dysfunction, infertility, and cosmetic purposes are not covered."

Both states bundle three of the six Section 1927(d)(2)(A) federal-statute optional-exclusion categories (weight loss + fertility + cosmetic). VT adds hair growth (the fourth federal-statute category); HI adds erectile dysfunction (a state-level non-statute addition). Vermont operationalizes three FDA-label carve-outs via drug-specific PA forms (Wegovy MACE + Wegovy MASH + Zepbound OSA). HI’s carve-out status is UNVERIFIED at the May 15, 2026 verification cutoff.

Where the two states diverge:

• Architecture: VT is FFS-only (CMS lists VT under PCCM); HI is mandatory managed care across 5 MCOs under 1115 demonstration
• 1115 history: VT operates state-plan authority with narrow waivers; HI operates a 32-year continuous 1115 demonstration covering all enrollees
• Reform bill activity: VT H.765 / S.164 (2024) stalled in committee with DVHA fiscal estimate "$75 million annually in drug costs within a few years"; HI SB 3195 (2026) remains in play with bipartisan sponsorship
• Geographic dispersion: VT is contiguous; HI has six islands with explicit MCO availability stratification
• Cost of living: VT index moderate; HI index 193.3 (highest in nation)
• Equity context: VT primarily white; HI majority NHPI / Asian with PMID 39574878 prescribing disparity

11.2 HI vs. Rhode Island Pattern #40 - inverse trajectory

RI Pattern #40 is the policy mirror of HI Pattern #50. RI currently covers Wegovy + Zepbound + Saxenda + Contrave for chronic weight management and is one of the 13 active-coverage states per KFF January 2026. The policy risk in RI is whether the General Assembly enacts Gov. McKee’s FY2027 October 1, 2026 sunset proposal. HI does NOT currently cover any of these for weight management; the policy opportunity in HI is whether the General Assembly enacts SB 3195 to scrap the exclusion. The two states are mirror images on the political-direction axis: RI faces an exclusion proposal from an incumbent Democratic governor; HI faces a reversal proposal from a Republican senator with bipartisan co-sponsors.

12. What Hawaii Med-QUEST beneficiaries should do right now

Five practical actions before the 2027 Hawaii legislative session and any potential SB 3195 enactment.

1. If you have T2D: the standard T2D pharmacy pathway applies. Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus, and Bydureon BCise are covered under all five Med-QUEST MCOs and FFS. PA submission via your MCO. UHC QUEST publishes the most operational detail: fax 866-940-7328, phone 1-800-310-6826, with adjudication "Allow at least 24 hours for review." For other MCOs, call the member-services line. Sen. Kurt Fevella’s personal example - "he takes Mounjaro for diabetes and has lost about 80 pounds" - illustrates the practical accessibility of the T2D pathway.

2. If you have established cardiovascular disease (prior MI, stroke, symptomatic PAD) AND no T2D AND want Wegovy for SELECT/MACE risk reduction: a Wegovy carve-out is UNVERIFIED in HI MCO PDLs but the FDA SELECT label provides the regulatory anchor for a medical-necessity exception. Pull the FDA Wegovy label and submit a PA to your MCO citing the cardiovascular indication (ICD-10 I25.x for chronic ischemic heart disease, I63.x for stroke, I73.9 for symptomatic PAD). If denied, exhaust MCO appeal (60-day filing, 30-day decision, expedited 3-business-day) then file state fair hearing within 120 days to DHS Administrative Appeals Office.

3. If you have moderate-to-severe OSA (AHI >= 15 with documented CPAP failure or intolerance) AND want Zepbound: the Zepbound OSA carve-out is UNVERIFIED in HI MCO PDLs but the FDA SURMOUNT-OSA label provides the medical-necessity anchor. Document the polysomnography AHI, CPAP failure or intolerance (90+ days of documented attempted use), and weight/BMI on the PA submission. ICD-10 G47.33 for obstructive sleep apnea.

4. If you are NHPI and have obesity: document the indication carefully on the medical record, work with a culturally-informed prescriber where possible, and reference Ka Wai Ola’s pairing framework (pharmacotherapy plus traditional foods, hula, surfing, walking, prayer, ho’oponopono) in clinical encounters. The PMID 39574878 prescribing disparity (adjusted OR 0.4 for NHPI vs White) is a known equity gap; documentation and active prescriber engagement materially reduce the gap. Engage with the Office of Hawaiian Affairs and Native Hawaiian Health Care Improvement Act-funded clinics where relevant.

5. Contact your state senator and representative (capitol.hawaii.gov) about SB 3195 - the bipartisan reversal bill remains in play for 2027 session even if 2026 sine die action did not advance it. Hawaii operates a two-year biennial legislative calendar, so 2026-session bills can carry into 2027. Track SB 3195 disposition at the Hawaii State Legislature website and LegiScan. Engage with Senate Health and Human Services Committee members and Ways and Means Committee members.

If you live on Moloka’i or Lana’i (or another rural island): engage your MCO member-services line about cold-chain mail-order pharmacy fulfillment options well in advance of any planned dose escalation. The interaction between geographic isolation, 2-8 C temperature requirements, and thin dispensing-location density on outer islands is operationally distinctive to Hawaii Pattern #50.

If your PA is denied: exhaust the MCO appeal (60-day filing, 30-day standard decision, expedited 3-business-day decision). If the MCO appeal is sustained, file a state fair hearing within 120 days to the DHS Administrative Appeals Office (P.O. Box 339, Honolulu, HI 96809-0339). Free legal representation is available through Legal Aid Society of Hawaii on request. Federal EPSDT (42 U.S.C. section 1396d(r)) provides additional regulatory anchor for beneficiaries under age 21.

If you cannot wait: the manufacturer self-pay channels listed in section 9.1 are accessible to Hawaii residents. NovoCare Wegovy ($199-$349/month tiered, $399/month HD pen, $149/month oral semaglutide), LillyDirect Zepbound vials ($299-$699/month), LillyDirect Foundayo ($149/month). Note the cold-chain shipping consideration for injectable pen formats. Compounded telehealth options are accessible at $99-$249/month but with the FDA compounding-resolved caveat.

13. Pattern #50 capstone summary

With Pattern #50 shipped, the WLR 50-state Medicaid GLP-1 coverage series is complete. Hawaii Pattern #50 sits at the intersection of nearly every dimension the series has examined:

• Regulatory exclusion architecture: categorical bundled exclusion (weight loss + erectile dysfunction + infertility + cosmetic) at MCO formulary level; not codified in state administrative rule (which is why SB 3195 directs "immediate and permanent rulemaking")
• Legislative reform attempts: SB 3195 (Sen. Kurt Fevella, 2026 Regular Session) with bipartisan co-sponsorship - the only state in the series with an active named bipartisan reversal bill at the verification cutoff
• 1115 demonstration governance: 32-year continuous "Hawaii QUEST Integration" demonstration since August 1, 1994 (longest in series); extended January 8, 2025 through December 31, 2029
• MCO concentration: five MCOs (AlohaCare, HMSA, Kaiser, ’Ohana, UHC) with Kaiser limited to O’ahu and Maui only - introducing explicit MCO-availability stratification by island
• Geographic dispersion: six major inhabited islands with cold-chain pen logistics (2-8 C) requiring inter-island temperature-monitored cargo
• Cost-of-living: 193.3 index (highest in nation) - magnifying the self-pay-burden alternative if Med-QUEST coverage is denied
• Racial-ethnic equity: PMID 39574878 documented adjusted OR 0.4 for NHPI vs White tirzepatide receipt
• Cultural framing: Ka Wai Ola (Office of Hawaiian Affairs publication) framing column by Dr. Jodi Leslie Matsuo emphasizing pharmacotherapy paired with traditional Hawaiian foods, hula, surfing, walking, prayer, and ho’oponopono

The series taxonomy is now documented in full. Future updates will track per-state policy changes through 2026-2027 budget cycles, individual SB 3195 progression in Hawaii, any post-sunset RI carve-out decisions, post-2027 ND HB 1451 / HB 1452 re-introduction attempts, and CA MASH-only coverage trajectory. The full 50-state pattern taxonomy is accessible at the State Medicaid GLP-1 Coverage hub.

For cross-state denial-recovery patterns applicable in any state, see the GLP-1 insurance dropped coverage appeal playbook. For the broader landscape of GLP-1 coverage across Medicare, Medicaid, and commercial, see the GLP-1 insurance coverage hub.

Related coverage

• Rhode Island Medicaid GLP-1 Coverage (Pattern #40) - active-coverage state with governor-proposed October 1, 2026 sunset; mirror image of HI on political-direction axis (RI removing coverage; HI adding coverage via SB 3195)
• Vermont Medicaid GLP-1 Coverage (Pattern #41) - closest formulary-language peer to HI: categorical bundled exclusion ("weight loss + fertility + cosmetic + hair growth") matching HI AlohaCare verbatim pattern; VT operationalizes three FDA-label carve-outs (Wegovy MACE + Wegovy MASH + Zepbound OSA), HI’s carve-outs UNVERIFIED; VT FFS-only vs. HI 5-MCO mandatory managed care under 32-year 1115 demonstration
• Kansas Medicaid GLP-1 Coverage (Pattern #43) - inverse coverage posture: KS positively covers Wegovy + Zepbound for obesity at adult BMI >= 30 or >= 27 with comorbidity and LOOSENED criteria in 2024-2025 by de-listing both drugs from Table 4; HI is the opposite - no current coverage but active bipartisan reversal bill
• Montana Medicaid GLP-1 Coverage (Pattern #46) - clean categorical chronic-weight-management exclusion under DPHHS / Mountain-Pacific Quality Health PA; HB 245 made expansion permanent (March 27, 2025) but SB 417 (Sen. Ellie Boldman AOM mandate) died 11-1 in committee March 1, 2025; PCCM (Passport to Health) architecture distinguishes from HI 1115 demonstration; both states have 2025-cycle decisive legislative rejection (MT) or active live bill (HI SB 3195)
• North Dakota Medicaid GLP-1 Coverage (Pattern #44) - middle-ground "covered for everything except obesity" with codified Wegovy MACE + Wegovy MASH + Zepbound OSA + Imcivree + antipsychotic-induced no-PA carve-outs; HB 1451 / HB 1452 FAILED 12-81 / 11-82 on House floor 02/12/2025 (most decisive legislative no-vote in series) - direct contrast to HI SB 3195 bipartisan live bill
• South Dakota Medicaid GLP-1 Coverage (Pattern #45) - functional exclusion-by-absence (no codified categorical sentence; OptumRx SD-specific GLP-1 PA form pre-codes only T2D); contrast to HI’s verbatim-codified categorical exclusion at AlohaCare formulary level; SD FFS-only vs. HI 5-MCO under 1115 demonstration
• Maine MaineCare GLP-1 Coverage (Pattern #39) - categorical exclusion with NO Wegovy MASH carve-out; LD 480 killed March 20, 2025
• West Virginia Medicaid GLP-1 Coverage (Pattern #36) - categorical exclusion with Wegovy CV + Zepbound OSA + Wegovy MASH carve-outs via WVU RDTP
• Mississippi Medicaid GLP-1 Coverage (Pattern #35) - only non-expansion southern positive-coverage state; SPA 23-0013 carve-back-in with pediatric ages 12+ pathway
• Delaware Medicaid GLP-1 Coverage (Pattern #42) - positive-coverage stable state with unified DMAP PDL across 3 MCOs; Section 1115 Diamond State Health Plan through December 31, 2028
• 50-state Medicaid GLP-1 coverage map (CAPSTONE / SERIES COMPLETE) - full series overview with complete pattern taxonomy
• GLP-1 insurance coverage hub - Medicare, Medicaid, and commercial coverage landscape
• GLP-1 insurance dropped coverage appeal playbook - denial-recovery patterns applicable across states

Primary sources

1. Hawaii Med-QUEST Division homepage
2. Med-QUEST Drug Coverage
3. MCO Formulary Search hub (links to all 5 MCO PDLs)
4. Med-QUEST five MCO health plans listing
5. Med-QUEST Grievance and Appeals (verbatim 120-day fair-hearing filing window, 90-day decision)
6. QUEST Integration 1115 demonstration page
7. CMS Hawaii QUEST Integration 1115 page (demo 11-W-00001/9)
8. Hawaii DHS Med-QUEST landing
9. AlohaCare QUEST formulary (verbatim weight-loss exclusion: "Drugs for weight loss, erectile dysfunction, infertility, and cosmetic purposes are not covered")
10. HMSA QUEST formulary (binary PDF)
11. Kaiser QUEST formulary PDF (binary)
12. ’Ohana QUEST pharmacy
13. UHC HI QUEST PDL (effective April 1, 2026; binary PDF)
14. UHC HI Community Plan pharmacy resources (fax 866-940-7328, phone 1-800-310-6826, "Allow at least 24 hours for review")
15. UHC HI pharmacy PA forms
16. HMSA QUEST appeals (verbatim 60-day filing, 30-day standard decision, 3-business-day expedited)
17. KITV - Hawaii senator wants weight-loss drugs to be covered by insurance (SB 3195, February 11, 2026)
18. Hoodline SB 3195 coverage (verbatim "scrap Hawaii’s current exclusion on GLP-1 drugs used to treat obesity")
19. Hawaii State Legislature SB 3195 (capitol.hawaii.gov)
20. LegiScan SB 3195
21. KFF Medicaid GLP-1 tracker (Jan 2026, HI NOT in 13-state active-coverage cohort)
22. KFF BALANCE Model brief
23. CMS BALANCE Model
24. The Rx Index 50-state tracker (HI verbatim: "Not covered. Diabetes GLP-1s covered.")
25. HHS Office of Minority Health NHPI obesity (verbatim "NHPI adults were 27% more likely than U.S. adults overall to have obesity")
26. America’s Health Rankings Hawaii (27.0% adult obesity rate)
27. Hawaii Health Data Warehouse obesity
28. PubMed PMID 39574878 (NHPI vs White tirzepatide receipt adjusted OR 0.4, 95% CI 0.3-0.6)
29. Ka Wai Ola (Office of Hawaiian Affairs) - Dr. Jodi Leslie Matsuo cultural framing column
30. Hawaii cost-of-living index 193.3 (highest in US)
31. BLS Honolulu CPI